Tumor markers assessed prior to the third treatment cycle showed a significant increase in CEA to 1,631.73 ng/mL, while CA125 and CA19–9 were 17.3 U/mL and 4.24 U/mL, respectively (Figure 1, August 22, 2021). This evidence concerns the gene CEACAM5 and neoplasm.